Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Capital Expenditures (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Capital Expenditures for 11 consecutive years, with $833000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to $833000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $973000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $919000.0 for FY2025, 9115.8% up from the prior year.
  • Capital Expenditures for Q4 2025 was $833000.0 at Crescent Biopharma, up from $132561.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $833000.0 in Q4 2025, with the low at $1.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $72901.9, with a median of $5102.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures crashed 99.96% in 2022, then skyrocketed 80000.0% in 2023.
  • Over 5 years, Capital Expenditures stood at $2447.0 in 2021, then plummeted by 99.96% to $1.0 in 2022, then surged by 80000.0% to $801.0 in 2023, then surged by 828.71% to $7439.0 in 2024, then skyrocketed by 11097.74% to $833000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $833000.0, $132561.0, and $7439.0 for Q4 2025, Q2 2025, and Q1 2024 respectively.